NCT01822028View on ClinicalTrials.gov

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions

Diarrhea

Interventions

DRUG

Treatment A

Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).

DRUG

Treatment B

"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."

Trial Locations (1)

M9L 3A2

BioPharma Services Inc., Toronto